Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321856329> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W2321856329 endingPage "10" @default.
- W2321856329 startingPage "10" @default.
- W2321856329 abstract "AVENTIS WILL PAY ANTI-sense drug developer Genta a possible $480 million for rights to its Genasense cancer-fighting drug. The deal is thought to be the second largest alliance around a single product, but it's worth considerably less than Bristol-Myers Squibb's $2 billion bid for ImClone Systems' anticancer agent Erbitux. Genta will get $135 million up front, including a $75 million equity investment by Aventis, and the remaining $345 million as milestone payments. Genta also projects that Aventis could spend another $390 million to cover nearly all development and commercialization costs. Genasense, the 14-year-old company's lead biotech product, is now in multiple late-stage clinical trials. The partners will jointly develop and market it in the U.S., while Aventis will have exclusive rights elsewhere. Genta is to receive royalties at a percentage it pegs in the comfortable double-digits. It will be responsible for U.S. regulatory filings and is already preparing to scale up production with ..." @default.
- W2321856329 created "2016-06-24" @default.
- W2321856329 creator A5063094677 @default.
- W2321856329 date "2002-05-06" @default.
- W2321856329 modified "2023-09-27" @default.
- W2321856329 title "CANCER DRUG DEAL" @default.
- W2321856329 doi "https://doi.org/10.1021/cen-v080n018.p010" @default.
- W2321856329 hasPublicationYear "2002" @default.
- W2321856329 type Work @default.
- W2321856329 sameAs 2321856329 @default.
- W2321856329 citedByCount "0" @default.
- W2321856329 crossrefType "journal-article" @default.
- W2321856329 hasAuthorship W2321856329A5063094677 @default.
- W2321856329 hasConcept C127413603 @default.
- W2321856329 hasConcept C144133560 @default.
- W2321856329 hasConcept C2780035454 @default.
- W2321856329 hasConcept C3020340455 @default.
- W2321856329 hasConcept C55587333 @default.
- W2321856329 hasConcept C71924100 @default.
- W2321856329 hasConcept C98274493 @default.
- W2321856329 hasConceptScore W2321856329C127413603 @default.
- W2321856329 hasConceptScore W2321856329C144133560 @default.
- W2321856329 hasConceptScore W2321856329C2780035454 @default.
- W2321856329 hasConceptScore W2321856329C3020340455 @default.
- W2321856329 hasConceptScore W2321856329C55587333 @default.
- W2321856329 hasConceptScore W2321856329C71924100 @default.
- W2321856329 hasConceptScore W2321856329C98274493 @default.
- W2321856329 hasIssue "18" @default.
- W2321856329 hasLocation W23218563291 @default.
- W2321856329 hasOpenAccess W2321856329 @default.
- W2321856329 hasPrimaryLocation W23218563291 @default.
- W2321856329 hasRelatedWork W2014542943 @default.
- W2321856329 hasRelatedWork W2015604768 @default.
- W2321856329 hasRelatedWork W2315608476 @default.
- W2321856329 hasRelatedWork W2810851952 @default.
- W2321856329 hasRelatedWork W2946241187 @default.
- W2321856329 hasRelatedWork W3015875055 @default.
- W2321856329 hasRelatedWork W3205561628 @default.
- W2321856329 hasRelatedWork W4210575590 @default.
- W2321856329 hasRelatedWork W4253758506 @default.
- W2321856329 hasRelatedWork W3119163977 @default.
- W2321856329 hasVolume "80" @default.
- W2321856329 isParatext "false" @default.
- W2321856329 isRetracted "false" @default.
- W2321856329 magId "2321856329" @default.
- W2321856329 workType "article" @default.